Physician profile
Bryan Harrell
NPI 1386143824
$934.94
in general payments reported to CMS, 2019-2025
15 companies · $20.71 in 2025
The $20.71 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $119 · 2024: $20.21 · 2025: $20.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $275.08 | 2021 | |
| Coloplast Corp | $151.94 | 2021-2025 | |
| Depuy Synthes Sales INC. | $73.87 | 2022 | |
| Clarus Therapeutics INC. | $69.42 | 2021 | |
| Janssen Biotech, INC. | $60.46 | 2021 | |
| Endo Pharmaceuticals INC. | $60.26 | 2021 | |
| Baxter Healthcare | $54.36 | 2021 | |
| 180 Medical, INC. | $54.16 | 2021 | |
| Blue Earth Diagnostics | $39.99 | 2021 | |
| Urovant Sciences INC | $23.10 | 2021 | |
| Chiesi USA, INC. | $16.02 | 2021 | |
| Myovant Sciences INC. | $15.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.32 | 2021 | |
| Amgen INC. | $13.94 | 2021 | |
| Teleflex LLC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.